On Nov. 2, 2020, CureVac announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate. The vaccine candidate was generally well tolerated across all tested doses and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation.

CVnCoV was also being investigated in a Phase 2a clinical trial in older adults in Peru and Panama.